JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has reinstated Denali Therapeutics (NASDAQ:DNLI) with an Overweight rating and set a price target of $28.

November 20, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics has been reinstated with an Overweight rating by JP Morgan analyst Jessica Fye, who set a price target of $28 for the stock.
The reinstatement of an Overweight rating by a major financial institution like JP Morgan, accompanied by a specific price target, is a strong positive signal to the market. This typically suggests a bullish outlook on the stock by the analyst and can lead to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100